"Novo Nordisk's Breakthrough Weight Loss Pill Poised to Outshine Competition"
TL;DR
Novo Nordisk CEO Lars Fruergaard Jørgensen believes the company's experimental weight loss pill, amycretin, could become a best-in-class treatment for obesity, potentially surpassing the success of its blockbuster drug Wegovy. Early-stage trial data showed patients on amycretin lost about 13.1% of their weight after 12 weeks, surpassing Wegovy's 6% weight loss. The pill targets gut hormone GLP-1 and pancreas hormone amylin, with a midstage trial expected to begin in the second half of 2022 and results anticipated in early 2026.
Topics:businesshealthcare#amycretin#clinical-trial#healthcare#novo-nordisk#obesity-treatment#weight-loss-pill
- Novo Nordisk CEO says experimental weight loss pill could become a best-in-class drug CNBC
- Ozempic or Tesla? Markets are in no doubt which is hotter CNN
- Novo Nordisk Shares Surge After Early Trial Shows New Obesity Drug Could Outperform Wegovy The Wall Street Journal
- Novo Nordisk confident of amycretin obesity drug launch this decade Reuters
- Novo Nordisk beats Tesla's market cap after new weight loss drug trial Quartz
Want the full story? Read the original reporting
Read on CNBC